Synergistic antiviral activity against human adenovirus through combination of itraconazole and brincidofovir
Given the gastrointestinal toxicity associated with brincidofovir, its combination with the host-directed drug itraconazole allowed lower brincidofovir doses to be used to decrease HAdV titres, thereby minimizing adverse drug effects while maintaining antiviral efficacy.
Authors
- Niklas Arnberg (ORCID: https://orcid.org/0000-0002-7069-6678)
- Elin Hahlin (ORCID: https://orcid.org/0000-0002-0505-533X)
- Britta F. Zecher
- Wing-Hang Ip (ORCID: https://orcid.org/0000-0002-5367-1401)
- Marcus Altfeld (ORCID: https://orcid.org/0000-0001-5972-2997)
- Sebastian Kühn (ORCID: https://orcid.org/0009-0000-5470-7181)
- Martin E. Baumdick (ORCID: https://orcid.org/0000-0001-5948-8109)
- Andrea Pirosu
- Christian Conze (ORCID: https://orcid.org/0000-0002-8849-1064)
- Sebastian Schloer (ORCID: https://orcid.org/0000-0002-9944-3017)
- Thomas Dobner (ORCID: https://orcid.org/0000-0001-7392-8588)
- Angelique Hölzemer (ORCID: https://orcid.org/0000-0002-1446-3474)
- Suzanne M. Linder
- Madeleine J. Bunders
- S. Post
- Mohamed Zamzamy
Institutions
- Leibniz Institute of Virology (LIV) (DE)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Umeå University (SE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1111/bph.70258
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- British Pharmacological Society
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- European Regional Development Fund
- European Observation Network for Territorial Development and Cohesion